BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 17187432)

  • 1. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
    Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
    Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.
    Katoh H; Ojima H; Kokubu A; Saito S; Kondo T; Kosuge T; Hosoda F; Imoto I; Inazawa J; Hirohashi S; Shibata T
    Gastroenterology; 2007 Nov; 133(5):1475-86. PubMed ID: 17983802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
    Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
    Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
    Xue KX
    Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
    Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
    Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
    Ladeiro Y; Couchy G; Balabaud C; Bioulac-Sage P; Pelletier L; Rebouissou S; Zucman-Rossi J
    Hepatology; 2008 Jun; 47(6):1955-63. PubMed ID: 18433021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.
    Zucman-Rossi J; Jeannot E; Nhieu JT; Scoazec JY; Guettier C; Rebouissou S; Bacq Y; Leteurtre E; Paradis V; Michalak S; Wendum D; Chiche L; Fabre M; Mellottee L; Laurent C; Partensky C; Castaing D; Zafrani ES; Laurent-Puig P; Balabaud C; Bioulac-Sage P
    Hepatology; 2006 Mar; 43(3):515-24. PubMed ID: 16496320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
    Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
    Ishizaki Y; Ikeda S; Fujimori M; Shimizu Y; Kurihara T; Itamoto T; Kikuchi A; Okajima M; Asahara T
    Int J Oncol; 2004 May; 24(5):1077-83. PubMed ID: 15067328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
    Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
    J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.
    Su H; Zhao J; Xiong Y; Xu T; Zhou F; Yuan Y; Zhang Y; Zhuang SM
    Mutat Res; 2008 May; 641(1-2):27-35. PubMed ID: 18358501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
    Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
    J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
    Yuan RH; Jeng YM; Chen HL; Hsieh FJ; Yang CY; Lee PH; Hsu HC
    Clin Cancer Res; 2005 Apr; 11(7):2568-75. PubMed ID: 15814635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
    Prange W; Breuhahn K; Fischer F; Zilkens C; Pietsch T; Petmecky K; Eilers R; Dienes HP; Schirmacher P
    J Pathol; 2003 Oct; 201(2):250-9. PubMed ID: 14517842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
    Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
    Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S; Trautwein C; Niehof M; Manns M
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic inactivation of the canonical Wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells.
    Wu Y; Li J; Sun CY; Zhou Y; Zhao YF; Zhang SJ
    Neoplasma; 2012; 59(3):326-32. PubMed ID: 22296502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.